In this study, we investigated the anti-inflammatory effects of Licania macrocarpa Cuatrec
methanol extract (Lm-ME) in vitro and in vivo and found pharmacological target
proteins of Lm-ME in TLR4-mediated inflammatory signaling. This extract reduced NO production and
mRNA expression of inflammatory
cytokines such as iNOS, COX-2,
IL-6, and IL-1β. In the NF-κB- and AP-1-mediated
luciferase reporter gene assay,
transcription factor activities decreased under cotransfection with MyD88 or TRIF. Phosphorylated
protein levels of Src, PI3K, IKKα/β, and IκBα as well as p50 and p65 in the NF-κB signal pathway were downregulated, and phosphorylation of TAK1, MEK1/2, MKK4/7, and MKK3/6 as well as ERK, JNK, and p38 was decreased in the
AP-1 signal pathway. Through overexpression of HA-Src and HA-TAK1, respectively, Lm-ME inhibited autophosphorylation of overexpressed
proteins and thereby activated fewer downstream signaling molecules. Lm-ME also attenuated
stomach ulcers in an HCl/EtOH-induced acute
gastritis model mice, and COX-2
mRNA expression and phosphorylated TAK1 levels in gastric tissues were diminished. The
flavonoids kaempferol and
quercetin were identified in the HPLC analysis of Lm-ME; both are actively anti-inflammatory. Therefore, these results suggest that Lm-ME can be used for anti-inflammatory remedy by targeting Src and TAK1.